High-resolution aberrometry

Article

Even without refned nomograms, new-generation aberrometry is contributing to better results

We have consistently found that uncorrected distance vision is the best predictor of patient satisfaction after laser vision correction. Moreover, every line of visual acuity, even beyond the 'ideal' of 20/20, results in greater patient satisfaction with the procedure and a greater likelihood of positive referrals.

Optical Express centres in the UK have been evaluating the efficacy of a new high-resolution aberrometer (iDesign, Abbott Medical Optics, Santa Ana, California, USA) for wavefront-guided laser vision correction.

Study design and results

The performance of the new aberrometer was evaluated in 675 eyes of 348 patients undergoing refractive surgery between May and October 2012. These patients presented with a wide range of preoperative refractive error. Preoperative sphere ranged from –9.50 D to +4.25 D (mean: –1.86 ± 2.42 D) and preoperative cylinder was as much as 5.50 D in some eyes (mean: –0.76 ± 0.83 D).

At one month, 90% of all eyes had a manifest spherical equivalent (MSE) within 0.50 D of intended correction and 97% were within 1.00 D. The linear regression for attempted versus achieved MSE was 1.01, with a very strong correlation coefficient (0.97). Monocular uncorrected visual acuity (UCVA) was 20/25 or better in 93% of eyes and 20/16 or better in more than 70% of eyes.

Most impressive were the astigmatism correction results. One month postoperatively, the mean cylinder had been reduced to –0.18 ± 0.25 D, and 95% of the eyes had visually insignificant (less than 0.5 D) of cylinder. This is the best cylinder correction I have ever seen following an excimer laser procedure.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.